3-FEA

1. 2026-10-02issueIssued info_card
2. 2026-10-02srcPharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion
3. 2026-10-02src4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis
4. 2026-10-02srcWithdrawal from 3-Fluoroethamphetamine induces hyperactivity and depression-like behaviors in male mice
5. 2026-10-02srcDesigner drugs: mechanism of action and adverse effects
6. 2026-10-02srcIdentification and characterization of the new psychoactive substance 3-fluoroethamphetamine in seized material
7. 2026-10-02srcLocomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats
8. 2026-10-02srcA First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State
9. 2026-10-02src4-Fluoroamphetamine in the Netherlands: more than a one-night stand
10. 2026-10-02srcQuantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues
11. 2026-10-02srcStructure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release
12. 2026-10-02srcTramadol: basic pharmacology and emerging concepts
13. 2026-10-02srcNeuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants
14. 2026-10-02srcSafety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
15. 2026-10-02srcNovel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
16. 2026-10-02srcMultimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.
17. 2026-10-02srcAmphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
18. 2026-10-02srcAcute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs
19. 2026-10-02src3-Fluoroethamphetamine - NCATS Inxight Drugs
20. 2026-10-02srcSchedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
21. 2026-10-02srcA simple and isocratic protein-based high performance liquid chromatography method for the enantioseparation of amphetamine derivatives
22. 2026-10-02src3-Fluoroethamphetamine
23. 2026-10-02src3-FEA
24. 2026-10-02publicationPublication — publishagent-psx
25. 2026-10-02revisionr1.a1
26. 2026-10-02rulingRuling — psx:substance/3-fea/proposal/article_section_proposals/232d94c8-a0a4-4943-aa5f-6ce66f32fa12founder
27. 2026-10-02rulingRuling — psx:substance/3-fea/proposal/article_section_proposals/58b35394-18ae-4c6a-b0c8-9bc257945974founder
28. 2026-09-04issueIssued emergency
29. 2026-09-04issueIssued info_card
30. 2026-09-04issueIssued notice
31. 2026-06-04proposal41 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
32. 2026-06-04publicationPublication — backfill
33. 2026-05-04revisionRevision 1
34. 2026-05-04absenceSearched ClinicalTrials.gov for "3-FEA fluoroethylamphetamine" — no results
35. 2026-05-04genGeneration — pipeline-v5 · with 3 morepipeline-v5
36. 2026-05-04rungeneration run

The same entries, as forms: six forms.